Filter By “Public Health”
Understanding the Long Term Effectiveness of Varying Doses of a New Therapy for Major Depression
A large biopharmaceutical client conducted a Phase II, 6-week, randomized, placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability and safety of a new oral medication in patients with major depressive disorder who were not responding to antidepressant therapy.
Health Data Trends Part I: Top Trends in Health Data Demand
As Head of Data Strategy at Datavant, I help clients find partners with relevant real-world data (RWD) for linkage to their own data or to create multi-partner linked datasets. These clients include pharmaceutical companies, health systems, government, payers, and analytics platforms. Connecting data helps them create a robust picture of patient health to accelerate research, improve care, and lower healthcare costs.
Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy
Amivantamab is an epidermal growth factor receptor (EGFR)-MET bispecific antibody with immune cell-directing activity.
Datavant Supports FDA Guidance with a Privacy-first Approach to Using Real World Evidence for Regulatory Decision Making
Datavant submitted comments on the recently issued FDA’s guidance that helped to clarify how real world data could be made “fit for purpose” in regulatory decision-making.